Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer
ConclusionNivolumab is associated to PAD enlargement, a potential marker of pulmonary hypertension, sometimes leading to lethal adverse events. Careful CT-scan and echocardiographic evaluation of PAD should be part of the therapeutic work-up of patients receiving Nivolumab, especially those suffering cancer-associated malnutrition.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | CT Scan | Drugs & Pharmacology | Hypertension | Lung Cancer | Non-Small Cell Lung Cancer | Nutrition | PET Scan | Pulmonary Hypertension